Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page & c5 @4 D p$ g8 {
! {! N! y- N! B& f& \. P
4 J; P4 B* A# u' jSub-category: h# F1 J! W, ^1 ^1 n
Molecular Targets
- j5 [$ Q7 [' u. `2 G! k
- z4 m5 _6 l; S& ^0 N
\7 A7 n! f8 }6 lCategory:
/ I( q! _; Q" e0 T2 y; J( NTumor Biology 5 ^6 `6 @! Y: @/ ^
6 V# n8 ]0 I3 l% ^- V, _7 s, s; [ n. A+ {4 O; b" N
Meeting: I) F+ K9 D# u* u$ O; |
2011 ASCO Annual Meeting
8 H( f9 G% S: Y
, D4 z& M" S: q' z" d+ n3 _3 D% r& e1 |5 N0 M0 g0 U0 [" u
Session Type and Session Title:
" M& Q/ a1 Q: hPoster Discussion Session, Tumor Biology
" S! c% R0 k: P( ]' r2 g5 I
, C9 }8 M( W* k- U T. }+ J. x- q. X! @) Q0 |3 g
Abstract No:
i* X2 ]3 B1 W10517 / A: r" r$ u4 j6 t; e1 t8 ^3 V; Q
% c, e6 b: t/ h' i5 L: G+ h
* c( S& f( {3 b: l! u6 z8 VCitation:! F! D) \0 B* j8 q( _
J Clin Oncol 29: 2011 (suppl; abstr 10517)
: B7 c/ \; r% \ f8 @
6 ]% {' v7 x9 N4 S* _! _, v. _9 |
Author(s):
+ a9 Y# p' e! [7 H3 yJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
; D) j; h# k1 l' U7 J m2 c
~0 a! N5 a) k/ f, N) `
8 ^. F C7 `' u- ~
; Z* _) @0 c& ^+ I2 }; XAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.4 W' {% `& W7 ]6 j. k, I0 N
& o- I% @( d+ q* r/ t9 f% g2 f
Abstract Disclosures$ w0 R% o- }0 t; P' |& v7 j3 C
G( @3 r ~1 B- E2 a+ f/ c
Abstract:$ f6 J/ N5 u9 T$ E
g8 @! A6 p3 ]2 b
8 h! j I; R w1 z- hBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.+ r3 U. d* N5 k$ p5 a- @0 c6 e2 g2 @
4 @7 s5 K! r k' o K+ v
2 p3 Z$ ]1 e* V/ h |
显身卡
